Table 3.
Summary of SMD of the clinical characteristics between the wild carriers and variant carriers
| All subjects | NAFLD group | |||||||
| N | SMD(95% CI) | Pa | I2 | N | SMD(95% CI) | Pa | I2 | |
| BMI | 5 | 0.16(-0.25,0.58) | 0.86 | 0 | 3 | 0.48(-0.04,0.99) | 0.83 | 0 |
| Waist | 2 | -0.09(-3.48,3.30) | 0.16 | 50 | ||||
| FPG | 5 | -1.18(-2.94,0.58) | 0.42 | 0 | 3 | -0.49(-4,27,3.29) | 0.19 | 40 |
| HOMA-IR | 4 | -0.06(-0.13,0.00) | 0.29 | 19 | 3 | -0.11(-0.22,0.01) | 0.60 | 0 |
| TG | 6 | -4.50(-19.36,10.35) | 0.005 | 70 | 3 | 2.69(-0.97,15.10) | 0.20 | 38 |
| HDL | 6 | 0.83(-0.68,2.34) | 0.19 | 33 | 3 | -3.09(-8.17,1.99) | 0.003 | 83 |
| LDL | 6 | 1.81(-6.09,9.71) | 0.004 | 72 | 3 | 4.02(-2.39,10.43) | 0.57 | 0 |
| TC | 3 | 1.37(-11.98,14.73) | 0.01 | 77 | ||||
| FINS | 2 | -0.06(-0.26,0.13) | 0.42 | 0 | ||||
| APOC3 | 2 | -1.38(-3.39,0.63) | 0.01 | 84 | ||||
| ALT | 2 | -0.01(-4.88,4.85) | 0.99 | 0 | ||||
| AST | 2 | -2.13(-5.65,1.38) | 0.47 | 0 | ||||
N: number of studies
a
Test for heterogeneity
BMI, body mass index; FPG, fasting blood glucose; HOMA-IR, homeostatic model assessment of insulin resistance; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; FINS, fasting blood insulin; APOC3, apolipoprotein C3; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAFLD, nonalcoholic fatty liver disease; SMD, standardized mean difference